Last updated: 2026-09-23 22:02:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Atara Biotherapeutics, Inc. (ATRA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.59, with a market capitalisation of $94.15M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.92 to $19.15. This page covers its latest market performance, valuation, price trends and company information.
$94.15M | |
$8.92 | |
$1,639.00 | |
$3.92 | |
$8.93 | |
39.01K | |
59.13K | |
-- | |
$19.15 | |
$3.92 | |
-- | |
-- |
Atara Biotherapeutics, Inc. (ATRA) is trading at $8.57 in after-hours trading as of 2026-09-23 20:11:00, down 4.09% ($0.37) from the regular-session close of $8.93.
After-hours trading shows how investors are pricing ATRA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Atara Biotherapeutics, Inc. (ATRA) moved from $9.25 to $8.59, representing a decline of 7.19% ($0.66).
The stock traded between $8.33 and $10.37 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 49.25 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 30.6%
ATRA is currently trading at $8.59, placing it 30.6% of the way from its 52-week low of $3.92 to its 52-week high of $19.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atara Biotherapeutics, Inc. (ATRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.